Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation

Clinical Chemistry

Volumn 47, Issue 5, 2001, Pages 858-866

  Ambrose, T M ^a   Parvin, C A ^a   Mendeloff, E ^a   Luchtman Jones, L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN;

ACCURACY; ADOLESCENT; ADULT; ANTICOAGULATION; ARTICLE; AUTOANALYZER; BLOOD CLOTTING TIME; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACORPOREAL OXYGENATION; HEMOSTASIS; HEPARINIZATION; HUMAN; INFANT; NEWBORN; PATIENT MONITORING; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 0035050444     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.5.858     Document Type: Article

References (22)

1. ECMO
2. Extracorporeal life support: The University of Michigan experience
3. Risk factors for intracranial hemorrhage in the extracorporeal membrane oxygenation patient
4. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Laboratory monitoring of unfractionated heparin therapy
5. Establishing a therapeutic range for heparin therapy
6. Heparin therapy during cardiopulmonary bypass requires ongoing quality control
7. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation
8. The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery
9. Predictive performance of three methods of activated clotting time measurement in neonatal ECMO patients
10. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations
11. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass
12. Anticoagulation practices during neonatal extracorporeal membrane oxygenation: Survey results
13. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients
14. Sensitivity and specificity of the Hemochron, Hemotec and APTT for the detection of Iow concentrations of heparin
15. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis
16. Robust regression
17. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro
18. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass
19. Efficacy and toxicity of heparin in relation to age and sex